Lifestyle Intervention Requirements for Novel Antiobesity Medications—Necessary Adjunct or Harmful Gatekeeper?

This Viewpoint discusses how prerequisite comprehensive lifestyle interventions for novel antiobesity medications may disproportionately impact patients at highest risk of obesity-related complications and perpetuate disparities in care.